TY - JOUR
T1 - Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease
T2 - Multinational Analysis From the ICARUS-IBD Consortium
AU - ICARUS-IBD Consortium
AU - Wong, Serre Yu
AU - Wellens, Judith
AU - Helmus, Drew
AU - Marlow, Luke
AU - Brann, Stephanie
AU - Pazos, Vicky Martinez
AU - Weinberg, Alan
AU - Moran, Hunter R.
AU - McGregor, Colleen
AU - Vermeire, Séverine
AU - Watanabe, Kenji
AU - Kamikozuru, Koji
AU - Ahuja, Vineet
AU - Vermani, Shubi
AU - Lindsay, James O.
AU - Kingston, Ashley
AU - Dutta, Usha
AU - Kaur, Harmandeep
AU - Silverberg, Mark S.
AU - Milgrom, Raquel
AU - Ng, Siew Chien
AU - Yan Mak, Joyce Wing
AU - Cadwell, Ken
AU - Thompson, Craig
AU - Colombel, Jean Frédéric
AU - Satsangi, Jack
AU - Ambrose, Tim
AU - Brain, Oliver
AU - Walsh, Alissa
AU - Klenerman, Paul
AU - Travis, Simon
AU - Edmans, Matthew
AU - Dixon, Rebekah
AU - Navalurkar, Reema
AU - Gold, Stephanie
AU - Lacoste, Joshua
AU - Chen, Clara
AU - Halfvarson, Jonas
AU - Bergemalm, Daniel
AU - Rubin, David T.
AU - Abreu, Maria T.
AU - Allez, Matthieu
AU - Neil, Jessica Anne
AU - Sota, Stela
AU - Jang, Kyung Ku
AU - Ching, Krystal
AU - Venzon, Mericien
AU - Yao, Xiaomin
AU - Bernard, Lucie
AU - Cowger, Tori L.
N1 - Publisher Copyright:
© The Author(s) 2023.
PY - 2023/11/1
Y1 - 2023/11/1
N2 - Background: Beyond systematic reviews and meta-analyses, there have been no direct studies of serological response to COVID-19 in patients with inflammatory bowel disease (IBD) across continents. In particular, there has been limited data from Asia, with no data reported from India. The ICARUS-IBD (International study of COVID-19 Antibody Response Under Sustained immunosuppression in IBD) consortium assessed serological response to SARS-CoV-2 in patients with IBD in North America, Europe, and Asia. Methods: The ICARUS-IBD study is a multicenter observational cohort study spanning sites in 7 countries. We report seroprevalence data from 2303 patients with IBD before COVID-19 vaccination between May 2020 and November 2021. SARS-CoV-2 anti-spike and anti-nucleocapsid antibodies were analyzed. Results: The highest and lowest SARS-CoV-2 anti-spike seropositivity rates were found in Asia (81.2% in Chandigarh and 57.9% in Delhi, India; and 0% in Hong Kong). By multivariable analysis, country (India: odds ratio [OR], 18.01; 95% confidence interval [CI], 12.03-26.95; P < .0001; United Kingdom: OR, 2.43; 95% CI, 1.58-3.72; P < .0001; United States: OR, 2.21; 95% CI, 1.27-3.85; P = .005), male sex (OR, 1.46; 95% CI, 1.07-1.99; P = .016), and diabetes (OR, 2.37; 95% CI, 1.04-5.46; P = .039) conferred higher seropositivity rates. Biological therapies associated with lower seroprevalence (OR, 0.22; 95% CI, 0.15-0.33; P < .0001). Multiple linear regression showed associations between anti-spike and anti-nucleocapsid titers with medications (P < .0001) but not with country (P = .3841). Conclusions:While the effects of medications on anti-SARS-CoV-2 antibody titers in patients with IBD were consistent across sites, geographical location conferred the highest risk of susceptibility to serologically detectable SARS-CoV-2 infection. Over half of IBD patients in India were seropositive prior to vaccination. These insights can help to inform shielding advice, therapeutic choices, and vaccine strategies in IBD patients for COVID-19 and future viral challenges.
AB - Background: Beyond systematic reviews and meta-analyses, there have been no direct studies of serological response to COVID-19 in patients with inflammatory bowel disease (IBD) across continents. In particular, there has been limited data from Asia, with no data reported from India. The ICARUS-IBD (International study of COVID-19 Antibody Response Under Sustained immunosuppression in IBD) consortium assessed serological response to SARS-CoV-2 in patients with IBD in North America, Europe, and Asia. Methods: The ICARUS-IBD study is a multicenter observational cohort study spanning sites in 7 countries. We report seroprevalence data from 2303 patients with IBD before COVID-19 vaccination between May 2020 and November 2021. SARS-CoV-2 anti-spike and anti-nucleocapsid antibodies were analyzed. Results: The highest and lowest SARS-CoV-2 anti-spike seropositivity rates were found in Asia (81.2% in Chandigarh and 57.9% in Delhi, India; and 0% in Hong Kong). By multivariable analysis, country (India: odds ratio [OR], 18.01; 95% confidence interval [CI], 12.03-26.95; P < .0001; United Kingdom: OR, 2.43; 95% CI, 1.58-3.72; P < .0001; United States: OR, 2.21; 95% CI, 1.27-3.85; P = .005), male sex (OR, 1.46; 95% CI, 1.07-1.99; P = .016), and diabetes (OR, 2.37; 95% CI, 1.04-5.46; P = .039) conferred higher seropositivity rates. Biological therapies associated with lower seroprevalence (OR, 0.22; 95% CI, 0.15-0.33; P < .0001). Multiple linear regression showed associations between anti-spike and anti-nucleocapsid titers with medications (P < .0001) but not with country (P = .3841). Conclusions:While the effects of medications on anti-SARS-CoV-2 antibody titers in patients with IBD were consistent across sites, geographical location conferred the highest risk of susceptibility to serologically detectable SARS-CoV-2 infection. Over half of IBD patients in India were seropositive prior to vaccination. These insights can help to inform shielding advice, therapeutic choices, and vaccine strategies in IBD patients for COVID-19 and future viral challenges.
KW - Inflammatory bowel disease
KW - SARS-CoV-2
KW - seroprevalence
UR - http://www.scopus.com/inward/record.url?scp=85176496256&partnerID=8YFLogxK
U2 - 10.1093/ibd/izad097
DO - 10.1093/ibd/izad097
M3 - 学術論文
C2 - 37354560
AN - SCOPUS:85176496256
SN - 1078-0998
VL - 29
SP - 1693
EP - 1705
JO - Inflammatory Bowel Diseases
JF - Inflammatory Bowel Diseases
IS - 11
ER -
